Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous...
Hence then, the article about nls pharmaceutics and kadimastem announce pricing and closing of 1 million equity financing was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing )
Also on site :
- Anycubic Opens Deposits for Kobra X, Following Formnext Debut of Its Next-Generation Entry-Level Multicolor FDM Printer
- AR Accessibility Research Wins AIS Impact Award 2025 with Support from LLVision Smart Glasses
- How Peso Pluma and Tito Double P Made ‘Dinastía,’ and Changed the Sound of Corridos